Orforglipron (Foundayo), explained.
Orforglipron (Foundayo), a daily GLP-1 tablet.
The form
Orforglipron (Foundayo) tablet
The routine
A daily tablet.
The evidence
Human clinical trials.
Read the guide for product directions and safety questions.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
What makes it different
Most GLP-1 drugs, including semaglutide and tirzepatide, are peptides. Orforglipron is a small molecule, which is why it survives digestion without the strict empty-stomach routine the Wegovy pill needs. You can take it any time of day.
What the trial showed
In ATTAIN-1, adults on the highest dose lost about 11 percent of their body weight over 72 weeks, compared with about 2 percent on placebo. That's less than the injections, and plenty for many people's goals.
Who it suits
- People who don't want to inject.
- People who travel a lot and would rather not manage pens.
- People whose goal is closer to 10 percent than 20.
Care and medication costs
Clinical care and medication have separate self-pay costs. We confirm the exact medication price before you start. See the pricing page.
Questions people ask
Foundayo or the Wegovy pill?
The Wegovy pill produced more average weight loss in its trial, about 14 percent against about 11, but it must be taken on an empty stomach with a small sip of water and a 30-minute wait. Orforglipron (Foundayo) can be taken with or without food. Medication costs depend on the exact prescription.
Is Foundayo a peptide?
No, and that's the point. It's a small molecule that acts on the same GLP-1 receptor.
Sources
- Research publicationOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) New England Journal of Medicine, 2025
- Research publicationOral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) New England Journal of Medicine, 2025
- Manufacturer informationOrforglipron (Foundayo) prescribing information Eli Lilly, Prescribing information checked October 6, 2026
Good days ahead.
Join the opening list for appointment updates.